Cargando…
Correlative studies of a Phase II clinical study of bavituximab and sorafenib in patients with advanced hepatocellular carcinoma
Autores principales: | Yopp, Adam, Kallinteris, Nikoletta, Huang, Xianming, Shan, Joe, Menander, Kerstin, Hutchins, Jeff, King, Steve, Xu, Xiaowei, Gabrilovich, Dmitry, Brekken, Rolf |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292436/ http://dx.doi.org/10.1186/2051-1426-2-S3-P214 |
Ejemplares similares
-
Antibody-mediated blockade of phosphatidylserine enhances the anti-tumor activity of targeted therapy and immune checkpoint inhibitors by affecting myeloid and lymphocyte populations in the tumor microenvironment
por: Yopp, Adam, et al.
Publicado: (2014) -
Profile of bavituximab and its potential in the treatment of non-small-cell lung cancer
por: Stasi, Irene, et al.
Publicado: (2014) -
A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer
por: Chalasani, Pavani, et al.
Publicado: (2015) -
Targeting phosphatidylserine synergizes with immune checkpoint blockade by inducing de novo tumor specific immunity
por: Huang, Xianming, et al.
Publicado: (2015) -
New method for immunoprofiling of the tumor microenvironment of cancer patients by opal multiplex quantitative immunofluorescence (IF) assay
por: Kallinteris, Nikoletta L, et al.
Publicado: (2015)